Frontiers in Medicine (Nov 2022)

Implementing HPV testing in 9 Latin American countries: The laboratory perspective as observed in the ESTAMPA study

  • Mary Luz Rol,
  • María Alejandra Picconi,
  • Annabelle Ferrera,
  • Gloria Inés Sánchez,
  • María de la Luz Hernández,
  • María de la Luz Hernández,
  • Joana Lineros,
  • Ana Peraza,
  • Marisol Brizuela,
  • Laura Mendoza,
  • Pamela Mongelós,
  • Yessy Cabrera,
  • Margarita Rodríguez de la Peña,
  • Rita Mariel Correa,
  • Carolina Terán,
  • Deisy Colque Reynaga,
  • Laura García,
  • Arianis Tatiana Ramírez,
  • Pilar Hernández-Nevarez,
  • Franco Doimi,
  • María Ramón,
  • Javier Arias-Stella,
  • Michael Zúñiga,
  • Verónica Villagra,
  • María Liz Bobadilla,
  • Lucía Cardinal,
  • Joan Valls,
  • Eric Lucas,
  • Armando Baena,
  • Laura Fleider,
  • Gino Venegas,
  • Gino Venegas,
  • Aurelio Cruz-Valdez,
  • Guillermo Rodríguez,
  • Alejandro Calderón,
  • Carolina Wiesner,
  • Silvana Luciani,
  • Nathalie Broutet,
  • Rolando Herrero,
  • Rolando Herrero,
  • Maribel Almonte,
  • Maribel Almonte

DOI
https://doi.org/10.3389/fmed.2022.1006038
Journal volume & issue
Vol. 9

Abstract

Read online

BackgroundReplacement of cytology screening with HPV testing is recommended and essential for cervical cancer elimination. HPV testing for primary screening was implemented in 12 laboratories within 9 Latin American countries, as part of the ESTAMPA cervical cancer screening study. Our observations provide information on critical operational aspects for HPV testing implementation in diverse resource settings.MethodsWe describe the implementation process of HPV testing in ESTAMPA, focusing on laboratory aspects. We assess the readiness of 12 laboratories to start HPV testing and their continuity capacity to maintain good quality HPV testing until end of recruitment or up to December 2021. Readiness was based on a checklist. Information from the study database; regular meetings and monitoring visits; and a questionnaire on laboratory operational aspects sent in May 2020 were used to assess continuity capacity. Compliance with seven basic requirements (readiness) and eight continuity requirements (continuity capacity) was scored (1 = compliant, 0 = not compliant) and totaled to classify readiness and continuity capacity as very limited, limited, moderate or high. Experiences, challenges, and enablers of the implementation process are also described.ResultsSeven of 12 laboratories had high readiness, three moderate readiness, and of two laboratories new to HPV testing, one had limited readiness and the other very limited readiness. Two of seven laboratories with high readiness also showed high continuity capacity, one moderate continuity capacity, and the other four showed limited continuity capacity since they could not maintain good quality HPV testing over time. Among three laboratories with moderate readiness, one kept moderate continuity capacity and two reached high continuity capacity. The two laboratories new to HPV testing achieved high continuity capacity. Based on gained expertise, five laboratories have become part of national screening programs.ConclusionHigh readiness of laboratories is an essential part of effective implementation of HPV testing. However, high readiness is insufficient to guarantee HPV testing high continuity capacity, for which a “culture of quality” should be established with regular training, robust monitoring and quality assurance systems tailored to local context. All efforts to strengthen HPV laboratories are valuable and crucial to guarantee effective implementation of HPV-based cervical screening.

Keywords